Cargando…
Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic
Anaphylaxis is a rare side-effect of COVID-19 vaccines. To (a) provide direct advice and reassurance to certain persons with a history of anaphylaxis/complex allergy, in addition to that available in national guidelines, and (b) to provide a medically supervised vaccination, a specialist regional va...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278227/ https://www.ncbi.nlm.nih.gov/pubmed/35753019 http://dx.doi.org/10.1093/cei/uxac064 |
_version_ | 1784746147356606464 |
---|---|
author | Lyons, Daniel Murray, Cliodhna Hannigan, Siobhan Sui, Jacklyn Alamin, Salma Conlon, Niall Keogan, Mary Khalib, Khairin Fitzpatrick, Chris O’B Hourihane, Jonathan Carey, Michael Edgar, J David M |
author_facet | Lyons, Daniel Murray, Cliodhna Hannigan, Siobhan Sui, Jacklyn Alamin, Salma Conlon, Niall Keogan, Mary Khalib, Khairin Fitzpatrick, Chris O’B Hourihane, Jonathan Carey, Michael Edgar, J David M |
author_sort | Lyons, Daniel |
collection | PubMed |
description | Anaphylaxis is a rare side-effect of COVID-19 vaccines. To (a) provide direct advice and reassurance to certain persons with a history of anaphylaxis/complex allergy, in addition to that available in national guidelines, and (b) to provide a medically supervised vaccination, a specialist regional vaccine allergy clinic was established. The main objective was to determine if risk stratification through history can lead to safe COVID-19 vaccination for maximum population coverage. A focused history was taken to establish contraindications to giving COVID-19 vaccines. People who reported a high-risk allergy history were given a vaccine not containing the excipient thought to have directly caused previous anaphylaxis. All vaccines were monitored for 30 min after administration. A total of 206 people were vaccinated between 6 July 2021 and 31 August 2021; Comirnaty (Pfizer-BioNTech) (n = 34), and Janssen (n = 172). In total, 78% were women. Ninety-two people (45%) reported a high-risk allergy history. There were no cases of anaphylaxis. Three people developed urticaria and one of these also developed transient tachycardia. One vaccinee developed a pseudoseizure. Two of 208 people (<1%) referred during this time declined vaccination based on personal preference, despite the assessment of low clinical risk. In our experience, all vaccines with high-risk allergy histories were administered Pfizer BioNTech or Janssen Covid-19 vaccines uneventfully following screening based on allergy-focussed history. Our data support that drug allergy is not associated with a higher risk of vaccine-related anaphylaxis but may act to guide the administration of alternate vaccines to people with polyethylene glycol/polysorbate 80/trometamol allergies or anaphylaxis after the first dose. |
format | Online Article Text |
id | pubmed-9278227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92782272022-07-18 Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic Lyons, Daniel Murray, Cliodhna Hannigan, Siobhan Sui, Jacklyn Alamin, Salma Conlon, Niall Keogan, Mary Khalib, Khairin Fitzpatrick, Chris O’B Hourihane, Jonathan Carey, Michael Edgar, J David M Clin Exp Immunol Research Articles Anaphylaxis is a rare side-effect of COVID-19 vaccines. To (a) provide direct advice and reassurance to certain persons with a history of anaphylaxis/complex allergy, in addition to that available in national guidelines, and (b) to provide a medically supervised vaccination, a specialist regional vaccine allergy clinic was established. The main objective was to determine if risk stratification through history can lead to safe COVID-19 vaccination for maximum population coverage. A focused history was taken to establish contraindications to giving COVID-19 vaccines. People who reported a high-risk allergy history were given a vaccine not containing the excipient thought to have directly caused previous anaphylaxis. All vaccines were monitored for 30 min after administration. A total of 206 people were vaccinated between 6 July 2021 and 31 August 2021; Comirnaty (Pfizer-BioNTech) (n = 34), and Janssen (n = 172). In total, 78% were women. Ninety-two people (45%) reported a high-risk allergy history. There were no cases of anaphylaxis. Three people developed urticaria and one of these also developed transient tachycardia. One vaccinee developed a pseudoseizure. Two of 208 people (<1%) referred during this time declined vaccination based on personal preference, despite the assessment of low clinical risk. In our experience, all vaccines with high-risk allergy histories were administered Pfizer BioNTech or Janssen Covid-19 vaccines uneventfully following screening based on allergy-focussed history. Our data support that drug allergy is not associated with a higher risk of vaccine-related anaphylaxis but may act to guide the administration of alternate vaccines to people with polyethylene glycol/polysorbate 80/trometamol allergies or anaphylaxis after the first dose. Oxford University Press 2022-06-26 /pmc/articles/PMC9278227/ /pubmed/35753019 http://dx.doi.org/10.1093/cei/uxac064 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com https://academic.oup.com/pages/standard-publication-reuse-rightsThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights) |
spellingShingle | Research Articles Lyons, Daniel Murray, Cliodhna Hannigan, Siobhan Sui, Jacklyn Alamin, Salma Conlon, Niall Keogan, Mary Khalib, Khairin Fitzpatrick, Chris O’B Hourihane, Jonathan Carey, Michael Edgar, J David M Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic |
title | Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic |
title_full | Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic |
title_fullStr | Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic |
title_full_unstemmed | Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic |
title_short | Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic |
title_sort | risk stratification through allergy history: single-centre experience of specialized covid-19 vaccine clinic |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278227/ https://www.ncbi.nlm.nih.gov/pubmed/35753019 http://dx.doi.org/10.1093/cei/uxac064 |
work_keys_str_mv | AT lyonsdaniel riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT murraycliodhna riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT hannigansiobhan riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT suijacklyn riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT alaminsalma riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT conlonniall riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT keoganmary riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT khalibkhairin riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT fitzpatrickchris riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT obhourihanejonathan riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT careymichael riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic AT edgarjdavidm riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic |